Dividend Channel
AMGN Dividend History & Description — Amgen Inc

Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).

Name:  Amgen Inc
Stock buyback:  AMGN buyback
Website:  www.amgen.com
Sector:  Biotechnology
Number of ETFs Holding AMGN:  134 (see which ones)
Total Market Value Held by ETFs:  $24,198,630,029.79
Total Market Capitalization:  $146,810,000,000
% of Market Cap. Held by ETFs:  16.48%
Name:  Amgen Inc
Stock buyback:  AMGN buyback
Website:  www.amgen.com
Sector:  Biotechnology
Number of ETFs Holding AMGN:  134 (see which ones)
Total Market Value Held by ETFs:  $24,198,630,029.79
Total Market Capitalization:  $146,810,000,000
% of Market Cap. Held by ETFs:  16.48%

AMGN Next Earnings Date »
AMGN Next Dividend Date »
(Projection based upon history)
AMGN Dividend Growth Rate »
Quotes delayed 20 minutes
Email EnvelopeFree AMGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


Buy (2.68 out of 4)
19th percentile
(ranked lower than approx. 81% of all stocks covered)

Analysts' Target Price:
AMGN Forecast

Based on data provided by Zacks Investment Research via Quandl.com


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Forum posts »



 

AMGN | Amgen Inc | Dividend History | Dividend Channel | www.DividendChannel.com | Copyright © 2010 - 2024, All Rights Reserved

Nothing in Dividend Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Dividend Channel; Meet Our Editorial Staff.